GlassScriptPhysician profile
Augusta Ify Nobel
NPI 1851955611
$823.85
in general payments reported to CMS, 2019-2025
13 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.95 · 2022: $66.46 · 2023: $106 · 2024: $32.63 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $185.73 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $162.07 | 2025 | Spravato |
| Abbvie INC. | $94.92 | 2022-2025 | |
| Braeburn INC. | $56.31 | 2025 | Brixadi |
| Indivior INC. | $51.72 | 2021-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $50.77 | 2022-2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.07 | 2025 | Caplyta |
| Gilead Sciences, INC. | $43.73 | 2025 | |
| Bioxcel Therapeutics, INC. | $40.80 | 2023 | Igalmi |
| Noven Therapeutics, LLC | $27.77 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $23.14 | 2025 | |
| Noven Pharmaceuticals, INC. | $22.35 | 2021 | |
| Alkermes, INC. | $19.47 | 2023 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusta Nobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.